- 01Semaglutide's effects on weight and labs last as long as the weekly dose does
Semaglutide lowers appetite, weight, A1C, triglycerides and blood pressure while it is in the body, and those changes fade once it is gone. In STEP 4, people who switched to placebo after 20 weeks regained 6.9% of their body weight over the next 48 weeks, while people who stayed on semaglutide lost a further 7.9% 3. In the STEP 1 extension, people had regained about two-thirds of their lost weight a year after stopping, and their gains in blood pressure, blood sugar and cholesterol had largely gone 4. So a good A1C or triglyceride result on semaglutide shows the drug is working, while the underlying condition is still there. Plan any change or stop with the prescriber, and expect to recheck the same blood tests a few months later.
Semaglutide works for as long as you take it. That explains why weight returns after stopping, and why A1C (the 3-month blood sugar average) and triglycerides (blood fats) improve on treatment and drift back off it. The same molecule sits in Ozempic, Wegovy, Rybelsus and the Wegovy pill. In trials it lowered weight, blood sugar, heart events and kidney events, and stomach side effects were the most common problem.
What semaglutide is and how it works
Semaglutide is a lab-made version of GLP-1 (glucagon-like peptide-1), a hormone the gut releases after a meal. Your own GLP-1 lasts only a few minutes in the blood before an enzyme called DPP-4 breaks it down. Semaglutide shares 94% of its sequence with human GLP-1 5, with two changes that keep it around: one swapped amino acid that DPP-4 cannot cut, and a fatty side chain that sticks to albumin, the main protein in blood. Those changes stretch semaglutide's half-life (the time it takes for half a dose to clear) to about a week 5, which is why one injection covers seven days. Medicines in this family are called GLP-1 receptor agonists, meaning drugs that switch on the same receptor as the natural hormone.
- In the pancreas, semaglutide raises insulin only when blood sugar is high and lowers glucagon, the hormone that tells the liver to release sugar. Because the insulin effect depends on glucose, semaglutide on its own rarely causes low blood sugar; taken with insulin or a sulfonylurea (an older diabetes pill such as glipizide that pushes insulin out whatever the blood sugar) it can 5.
- In the stomach, semaglutide slows emptying, so a meal stays longer and fullness lasts.
- In the brain, semaglutide acts on appetite centres, so hunger and food cravings fall and people eat less.
The weight loss on semaglutide comes from eating less, because the drug turns appetite down. The slowed stomach is also why most side effects sit in the gut. Semaglutide is used for type 2 diabetes, for weight loss in obesity, and now for fatty liver with scarring.
How Ozempic, Wegovy, Rybelsus and the Wegovy pill differ
Ozempic and Wegovy are the same molecule in the same kind of weekly pen. Wegovy climbs to a higher dose (2.4 mg a week, or 7.2 mg as Wegovy HD, against Ozempic's 2 mg) and carries the weight, heart and liver approvals; Ozempic is labelled for type 2 diabetes and the heart and kidney risks that come with it 7. Rybelsus and the Wegovy pill are daily tablets of the same drug, which needs far larger doses by mouth because little survives the stomach.
| Brand | Form | Highest labelled dose | FDA-approved for | First approved |
|---|---|---|---|---|
| Ozempic | Weekly injection | 2 mg | Blood sugar in type 2 diabetes; lower heart attack, stroke and cardiovascular death risk in type 2 diabetes with heart disease; lower kidney failure risk in type 2 diabetes with chronic kidney disease (added 2025) 7 | 2017 |
| Rybelsus | Daily tablet | 14 mg (original tablet) | Blood sugar in type 2 diabetes; lower heart attack, stroke and cardiovascular death risk in type 2 diabetes at high heart risk (added 2025) 8 | 2019 |
| Wegovy injection | Weekly injection | 2.4 mg | Chronic weight management from age 12; lower heart attack, stroke and cardiovascular death risk in adults with heart disease and overweight or obesity (2024); MASH, fatty liver with inflammation and moderate to advanced scarring (2025) 5 | 2021 |
| Wegovy HD | Weekly injection | 7.2 mg | Further weight loss and keeping it off in some adults with obesity 21 | March 2026 |
| Wegovy pill | Daily tablet | 25 mg | Weight loss and keeping it off in adults 20 | December 2025 |
What the trials showed, including the misses
| Trial | Who took part | What happened |
|---|---|---|
| STEP 1, 68 weeks 1 | 1,961 adults with obesity or overweight, no diabetes | Average weight loss 14.9% on weekly 2.4 mg, 2.4% on placebo |
| OASIS 4, 64 weeks 12 | 307 adults with obesity or overweight, no diabetes | Daily 25 mg pill: average weight loss 13.6%, against 2.2% on placebo |
| STEP UP, 72 weeks 13 | 1,407 adults with obesity, no diabetes | Weekly 7.2 mg: 18.7% average weight loss, against 15.6% on 2.4 mg and 3.9% on placebo |
| SELECT, about 40 months 2 | 17,604 adults with heart disease and overweight or obesity, no diabetes | Heart attack, stroke or cardiovascular death in 6.5% against 8.0% on placebo, a 20% lower risk |
| SUSTAIN-6, 2 years 11 | 3,297 people with type 2 diabetes at high heart risk | 26% fewer heart attacks, strokes and cardiovascular deaths, but more diabetic eye complications (3.0% against 1.8%) |
| STEP 4, 48 weeks after a 20-week start 3 | 803 adults who had already lost weight on semaglutide | Staying on it: a further 7.9% lost. Switching to placebo: 6.9% regained |
| FLOW, median 3.4 years 9 | 3,533 people with type 2 diabetes and chronic kidney disease | Major kidney events, including kidney failure, 24% less likely |
| ESSENCE, 72 weeks 10 | 800 people with MASH and moderate to advanced liver scarring | Liver inflammation cleared without worse scarring in 62.9% against 34.3% on placebo |
| EVOKE and EVOKE+, 2 years 19 | 3,808 people with early Alzheimer's disease | Oral semaglutide did not slow decline in memory and thinking |
Results varied widely in STEP 1: about a third of people on semaglutide lost 20% or more of their body weight, while about 1 in 7 lost less than 5% 1. No test predicts in advance which group a person will land in.
How a course of semaglutide starts
Every semaglutide label starts low on purpose. Nausea and vomiting track the dose increases, so each step is held for 4 weeks before the next. The prescriber sets the pace and can hold a step for longer, or stay on a lower dose, when side effects are rough. The table shows the schedule printed in the Wegovy label; it is for reading a prescription, not for setting your own dose. Ozempic uses different steps (0.25, 0.5, 1 and then 2 mg, each after at least 4 weeks) 7, and Wegovy HD adds a 7.2 mg step for some adults already on 2.4 mg 21.
| Weeks | Wegovy weekly injection on the label 5 |
|---|---|
| 1 to 4 | 0.25 mg (a starting step, not a treatment dose) |
| 5 to 8 | 0.5 mg |
| 9 to 12 | 1 mg |
| 13 to 16 | 1.7 mg |
| 17 onward | 2.4 mg maintenance, or 1.7 mg if 2.4 mg is not tolerated |
Taking a daily semaglutide pill
How long semaglutide takes to work
- First few weeks: appetite usually falls early, often on the starting doses, well before weight loss is obvious on the scale.
- About 3 months: A1C reflects roughly 3 months of blood sugar, so the full drop shows on a test at about that point.
- Months 3 to 15: most of the weight comes off in this stretch; in STEP 1 the average weight curve flattened from about week 60 1.
Side effects and how common they are
| Side effect | Adults on Wegovy | Adults on placebo |
|---|---|---|
| Nausea | 44% | 16% |
| Diarrhea | 30% | 16% |
| Vomiting | 24% | 6% |
| Constipation | 24% | 11% |
| Tummy pain | 20% | 10% |
These are the typical GLP-1 side effects, and the figures come from the Wegovy weight trials 5. Stomach side effects usually start or worsen in the days after a dose increase and ease over the following weeks. Smaller meals, stopping at the first sign of fullness and going easy on fatty food are the usual first steps, with more fiber, such as psyllium, and plenty of fluids for constipation. Semaglutide also raises resting heart rate by 1 to 4 beats a minute on average 5.
Serious risks and who should not take semaglutide
- Thyroid: semaglutide carries a boxed warning, the FDA's strongest label warning, because it caused tumors of the thyroid's C-cells (the cells that make calcitonin) in preclinical studies; whether that happens in people is unknown. Anyone with a personal or family history of medullary thyroid cancer or MEN2 (multiple endocrine neoplasia type 2, an inherited condition that causes gland tumors) should not take it 5.
- Pancreatitis, gallbladder disease and gallstones, and kidney injury from dehydration after vomiting or diarrhea are listed warnings 5.
- Diabetic eye disease: in SUSTAIN-6, people with type 2 diabetes on semaglutide had more retinopathy complications, 3.0% against 1.8%, most often when blood sugar fell fast from a high start 11.
- NAION, a sudden loss of blood flow to the optic nerve: the European Medicines Agency concluded in June 2025 that NAION is a very rare side effect of semaglutide, affecting up to 1 in 10,000 users 15.
- Sedation and anesthesia: food can stay in a slowed stomach and be breathed in, so the label says to tell the team before any procedure 5.
- Pregnancy: semaglutide is not used in pregnancy, and the label advises stopping at least 2 months before a planned pregnancy, because semaglutide takes weeks to leave the body 5.
Medicines and habits that interact with semaglutide
- Insulin and sulfonylureas (such as glipizide): the combination can cause low blood sugar, so prescribers often lower those doses when semaglutide starts 5.
- Pills that need steady absorption: a slower stomach can change how other medicines are absorbed. The Rybelsus label reports higher levothyroxine levels when the two are taken together 8, so your prescriber may recheck your TSH a few weeks after starting.
- Other GLP-1 drugs, including tirzepatide: the label says semaglutide should not be used together with another GLP-1 receptor agonist 5.
- Alcohol: adds to nausea and dehydration, and with insulin or a sulfonylurea adds to the low blood sugar risk.
Muscle loss, protein and eating less
Some of the weight lost on semaglutide is muscle and other lean tissue. In a STEP 1 substudy that measured body composition with DEXA scans, lean mass made up roughly 40% of the weight lost, although the share of the body that was lean rose because fat fell faster 1. Resistance training and eating enough protein help hold on to muscle while eating less; the protein calculator gives a daily target from body weight.
CalculatorProtein calculatorTurns your body weight into a daily protein range, useful when semaglutide shrinks your appetiteWork it out Eating a lot less for months also leaves less room for iron-rich and B12-rich foods. Ferritin and B12 are two results worth asking the prescriber about if appetite has dropped sharply, and B12 doubly so for anyone also on metformin, which can lower B12 over years; B12 deficiency covers the symptoms.
Blood tests on semaglutide: before you start and what changes
In STEP 1, semaglutide improved A1C, fasting glucose, triglycerides, blood pressure, waist size and C-reactive protein compared with placebo 1. Those changes are easiest to read against a starting point: a baseline A1C, lipid panel, liver panel and kidney panel before the first dose, A1C again at about 3 months, and ferritin and B12 if you are eating far less than before. Bring the old and new results to the same appointment so the prescriber can compare them.
| Result | Usual change on semaglutide | When to raise it with the prescriber |
|---|---|---|
| A1C and fasting glucose | Down; the A1C change shows within about 3 months 1 | A rising A1C on a steady dose |
| Triglycerides | Down 1 | A rise, which is not the expected direction |
| ALT and GGT (liver enzymes) | May fall as liver fat falls | A rise with yellow skin or upper right tummy pain |
| hs-CRP (inflammation) | Down 1 | Rarely matters on its own |
| Creatinine and eGFR (kidney filtration) | Usually stable | Creatinine up and eGFR down after vomiting or diarrhea, a sign of dehydration 5 |
| Lipase and amylase | Can rise with no pancreatitis 5 | Straight away with severe tummy pain spreading to the back |
| Ferritin and B12 | May drift down when eating far less | A low result, or new tiredness, pins and needles or breathlessness |
For the panels themselves, liver enzymes explained and kidney function explained go line by line. The semaglutide label lists raised lipase and amylase, both pancreas enzymes, among its lab findings, and says their meaning is unknown without other signs or symptoms of pancreatitis 5. A high lipase result on a routine panel, with no tummy pain, usually leads to a repeat test; the same result with severe pain spreading to the back needs urgent care. A GLP-1 blood test measures your own hormone; it is a research test and does not show how much semaglutide is in the body or whether the dose is right.
Markers to read on semaglutide

What happens when you stop semaglutide
In the STEP 1 extension, people who stopped at 68 weeks had regained about two-thirds of the weight they had lost a year later, and their improvements in blood pressure, A1C and cholesterol had largely gone too 4. The trial's authors drew a plain conclusion.
Findings confirm the chronicity of obesity and suggest ongoing treatment is required to maintain improvements in weight and health.Wilding et al., STEP 1 trial extension, Diabetes Obes Metab 2022 4
Anyone thinking of stopping or tapering does better planning it with the prescriber and rechecking A1C and lipids a few months after; how to read your lipid panel explains each line.
Compounded and online semaglutide
During the shortage that began in 2022, US pharmacies were allowed to compound copies of semaglutide. The FDA declared the semaglutide shortage resolved on 21 February 2025, and the grace periods ended on 22 April 2025 for local compounding pharmacies and 22 May 2025 for large-scale outsourcing facilities 16. Some telehealth sellers still offer compounded semaglutide under narrower rules, and the FDA does not review these products before sale.
This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.US Food and Drug Administration, on compounded GLP-1 drugs 6
The FDA also warns that some compounded products contain semaglutide sodium or semaglutide acetate, salt forms that are different active ingredients from the approved drug, and that it knows of no lawful basis for compounding with them 6. The agency has received reports of adverse events, some needing hospital care, from people measuring and injecting the wrong dose of compounded semaglutide 6. Approved Ozempic and Wegovy come in prefilled pens that deliver a set dose; a vial and syringe measured in units is a compounded format, and the mg doses on this page do not convert directly to units on a compounded vial. If you have injected more than intended, or have severe vomiting, cannot keep fluids down, or feel faint or confused after a dose, get medical help the same day.
Semaglutide vs tirzepatide and the next drugs
Tirzepatide (Mounjaro, Zepbound) acts on the GLP-1 receptor and a second gut-hormone receptor, GIP. In SURMOUNT-5, the first head-to-head weight trial, 751 adults on tirzepatide lost an average 20.2% of body weight at 72 weeks against 13.7% on semaglutide 14. Newer drugs add more hormone targets or swap the injection for a pill; the retatrutide vs semaglutide comparison sets out the triple-hormone shot against semaglutide in numbers.
Link · New England Journal of Medicine, 2025Tirzepatide as compared with semaglutide for the treatment of obesityThe SURMOUNT-5 trial: 751 adults with obesity and no diabetes, randomised to tirzepatide or semaglutide for 72 weeks.nejm.orgRelated drugs and medicines
Citations
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389(24):2221-2232.
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425.
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564.
- Novo Nordisk. Wegovy (semaglutide) injection, US prescribing information. Revised 2025.
- US Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss.
- Novo Nordisk. Ozempic (semaglutide) injection, US prescribing information.
- Novo Nordisk. Rybelsus (semaglutide) tablets, US prescribing information.
- Perkovic V, Tuttle KR, Rossing P, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med. 2024;391(2):109-121.
- Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE). N Engl J Med. 2025;392(21):2089-2099.
- Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375(19):1834-1844.
- Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025;393(11):1077-1087.
- Wharton S, Freitas P, Hjelmesæth J, et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol. 2025;13(11):949-963.
- Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36.
- European Medicines Agency. PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy. June 2025.
- US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. 2025.
- US Food and Drug Administration. Update on FDA's ongoing evaluation of reports of suicidal thoughts or actions in patients taking a certain type of medicines approved for type 2 diabetes and obesity. January 2024.
- European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC), 8-11 April 2024.
- Novo Nordisk. Evoke phase 3 trials did not demonstrate a statistically significant reduction in Alzheimer's disease progression. Company announcement, 24 November 2025.
- Novo Nordisk. FDA approves oral Wegovy pill. Press release, 22 December 2025.
- US Food and Drug Administration. FDA approves fourth product under National Priority Voucher program, higher dose semaglutide. 19 March 2026.
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.










